CTA Community Poll
We asked readers to weigh in on how they handle the topic of obesity with their patients and the results were surprising.
We asked our readers about their experience in dealing with issues surrounding the discussion of palliative care with their patients.
We asked readers how often they read oncology news and journal articles and what their most trusted sources were.
We asked our readers about their work/life balance as it relates to their oncology-related careers.
This slideshow reviews drug information for ABRAXANE® (paclitaxel protein-bound particles) (albumin-bound), indicated for adenocarcinoma of the pancreas.
This slideshow reviews ABRAXANE® (paclitaxel protein-bound particles) (albumin-bound) for patients with non-small cell lung cancer.
This slideshow reviews drug information for ADCETRIS™ (brentuximab vedotin).
Review drug information for AFINITOR® (everolimus) for treatment of neuroendocrine tumors of the pancreas.
This slideshow reviews drug information for AKYNZEO® (netupitant/palonosetron), indicated for chemotherapy-induced nausea and vomiting.
Review drug information for ALIMTA® (pemetrexed).
This slideshow reviews drug information for ARZERRA® (ofatumumab).
Review drug information for AVASTIN® (bevacizumab).
This slideshow reviews drug information for BELEODAQ® (belinostat).
This slideshow reviews drug information for BOSULIF® (bosutinib).
This slideshow reviews drug information for COMETRIQ™ (cabozantinib).
This slideshow reviews drug information for GAZYVA® (obinutuzumab)
This slideshow reviews drug information for GRANIX® (tbo-filgrastim) for management of severe neutropenia.
This slideshow reviews drug information for ICLUSIG™ (ponatinib).
This slideshow reviews drug information for IMBRUVICA® (ibrutinib), indicated for mantle cell lymphoma.
Review drug information for INLYTA®, indicated for advanced renal cell carcinoma.
Review drug information slides for JAKAFI® (ruxolitinib), indicated for treatment of myelofibrosis.
This slideshow reviews drug information for KADCYLA™ (ado-trastuzumab emtansine).
This slideshow reviews drug information for KEYTRUDA® (pembrolizumab).
This slideshow reviews drug information for KYPROLIS (carfilzomib), indicated for refractory multiple myeloma.
Although there's still a long road ahead in terms of achieving meaningful use incentives, this slideshow explores the history of EHR devices.
This slideshow reviews the uses, benefits, types, side effects, and toxicities associated with radiation therapy.
There are several known adverse events associated with the disease and its treatment, including venous thrombosis, pain, and malignant biliary obstruction.
Patients present with anorexia and a loss of skeletal muscle mass and adipose tissue, with treatment goals revolving around restoring muscle mass and body weight, while preventing further loss.
CAM is used as an adjunct to traditional therapies in an effort to provide supportive care in improving symptom control and patient well-being.
Gliomas are the most common form of brain tumors, which begin in the glial (supportive) tissue.
Patients receiving treatment for cancer can experience a number of potential side effects and reactions.
Compared to the severe adverse effects of chemotherapy, chemotherapy-induced alopecia (CIA) is surprisingly one of the more troubling aspects.
MP is a 38-year-old woman who comes to the clinic with a temperature of 101F and complains of abdominal pain approximately 14 days after her last chemotherapy treatment.
Colorectal cancer is the 3rd most common cancer, and the 2nd most common cause of death in the United States.
Retinoblastoma is a rare cancer that is caused by a mutation in the retinoblastoma gene (RB1) controlling cell division of the retina.
Ewing sarcoma is one of a group of cancers known collectively as the Ewing sarcoma family of tumors.
Breast cancer is the most commonly diagnosed cancer among women in the U.S. besides skin cancer.
More people in the United States die from lung cancer than any other type of cancer. This is true for both men and women.
Melanoma is the most dangerous type of skin cancer, and the most deadly.
The incidence of cancer diagnoses is increasing worldwide as the world’s population grows and people continue to live longer.
More than 40% of patients undergoing chemotherapy develop some degree of mucositis during the course of their treatment.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Multiple myeloma: Optimal management and long-term disease control
- Coffee May Decrease Risk of Malignant Melanoma
- ASCO Announces Chronic Leukemia Treatment as Cancer Advance of the Year
- LDVP Regimen Following Radiotherapy Effective for Stage III/IV T-Cell Lymphoma
- Brentuximab Vedotin Demonstrates Significant Activity in B-Cell Lymphoma
- Surveillance Until Rituximab Retreatment Does Not Increase Anxiety in Non-Hodgkin Lymphoma
- Contraceptive Use Linked to Higher Risk of Glioma
- Bevacizumab Plus Temozolomide Produces Low Response in Newly-Diagnosed Glioblastoma
- Standard-Dose vs. High-Dose Chemoradiotherapy With, Without Cetuximab for Lung Cancer
- Abiraterone Acetate Prolongs Survival in Metastatic Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|